口服双膦酸盐降低丹麦因骨密度检测转诊患者的心血管事件风险:一项队列研究
在丹麦因骨密度检测转诊的≥45岁人群中,2565例口服双膦酸盐使用者与4568例倾向评分匹配对照相比,心血管事件住院风险降低(校正HR 0.68,95%CI 0.60-0.77),额外校正骨密度后结果未减弱(HR 0.67,95%CI 0.58-0.78),房颤、卒中、心衰和动脉瘤风险亦降低。
要点
- 口服双膦酸盐使用者心血管事件住院风险较匹配对照降低(校正HR 0.68,95%CI 0.60-0.77)。
- 额外校正骨密度后HR为0.67(95%CI 0.58-0.78),结果未减弱。
- 房颤、卒中、心衰和动脉瘤等次要结局亦见风险降低。
核心结论
- 口服双膦酸盐使用者心血管事件风险降低33%,这一真实世界观察性研究为口服双膦酸盐的心脏保护作用增添了证据,但需在随机对照研究中验证。
研究设计与样本
- 队列研究,纳入丹麦因骨密度检测转诊的≥45岁人群,数据来自丹麦国家处方登记库并补充欧登塞当地医院数据,比较口服双膦酸盐使用者与倾向评分匹配对照。
主要发现
- 口服双膦酸盐使用者2565例(女性82.6%),匹配对照4568例(女性82.3%),阿仑膦酸钠占口服双膦酸盐处方的96%。
- 口服双膦酸盐组发生心血管事件406例(15.8%),发生率73.48(66.67-80.98);对照组837例(18.3%),发生率104.73(97.87-112.07)。
- 校正后HR为0.68(95%CI 0.60-0.77),额外校正骨密度后HR为0.67(95%CI 0.58-0.78)。
- 次要结局中房颤、卒中、心衰和动脉瘤风险降低;阳性和阴性对照结局分析显示残余混杂极小。
局限性
- 原文结论指出该观察性真实世界研究结果需在随机对照研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The cardiovascular (CV) safety of oral bisphosphonates (oBPs) is uncertain. OBJECTIVE: Determine the risk of CV events in oBP users referred for bone mineral density (BMD) testing compared with matched controls. DESIGN: Cohort study. SETTING: Danish national prescription registry enriched with local hospital data from Odense. PARTICIPANTS: Individuals aged ≥45 years referred for BMD testing. EXPOSURE: oBP. OUTCOMES: Hospitalization for any CV event. Secondary study outcomes were specific CV events. Negative (inguinal hernia surgery and ingrown toenail) and positive (fragility fracture) control outcomes assessed systemic bias. Cox proportional hazards models were fitted to estimate hazard ratio (HR) and 95% confidence intervals. RESULTS: There were 2565 oBP users (82.6% women) and 4568 (82.3% women) propensity score-matched controls. Alendronate accounted for 96% of oBP prescription. A total of 406 (15.8%) CV events occurred in oBP users (rate = 73.48 [66.67-80.98]); rate = events divided by person-time; and 837 (18.3%) events in controls (rate = 104.73 [97.87-112.07]) with an adjusted HR of 0.68 (95% CI 0.60-0.77). Additional adjustment for BMD did not attenuate estimates (HR 0.67; 95% CI 0.58-0.78]. Similar results were seen for secondary outcomes where risk reductions were seen regarding atrial fibrillation, stroke, heart failure, and aneurysms. Positive and negative control outcome analyses identified minimal residual confounding. CONCLUSION: Oral BP users experienced a 33% reduced risk of CV events. This observational real-world study adds to a growing body of evidence for cardioprotection by oBP that warrants testing in a randomized setting.
引用
- Rodríguez AJ, Ernst MT, Nybo M, et al. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. J Clin Endocrinol Metab. 2020. PMID: 32717068. doi:10.1210/clinem/dgaa481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。